Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=award_amount" }, "data": [ { "type": "Grant", "id": "6431", "attributes": { "award_id": "3U19AI057229-17S1", "title": "Influenza responses and repertoire in vaccination, infection and tonsil organoids.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21609, "first_name": "Chao", "last_name": "Jiang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-19", "end_date": "2022-03-31", "award_amount": 3874619, "principal_investigator": { "id": 21610, "first_name": "Mark Morris", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Wuhan, China is the epicenter of a rapidly spreading pandemic the World Health Organization (WHO) has officially designated as COVID-19. COVID-19 is caused by SARS-CoV-2, but how it is spread from person to person is still unclear. The asymptomatic presentation of the disease, and widespread travel out of Wuhan have permitted its rapid dissemination. As of March 16, 2020, there are over 175,000 cases affecting 162 countries with over 6,700 fatalities worldwide. SARS-CoV-2 is positive-sense RNA virus infecting vertebrate hosts that exists in a group of closely related co-evolving entities of which two others – SARS-CoV and MERS-CoV – have caused recent epidemics. Due to the complexity of anti-viral immunity, experience with other viruses has shown that swift success in vaccine development is by no means assured. A major challenge is the difficulty in adequately characterizing T cell-mediated recognition of viral epitopes. Finding the major shared specificities in COVID-19 subjects will help us understand what the most important CD4+ and CD8+ T cell responses will be. These findings can be deployed to determine the optimal vaccine formulation so as to elicit these T cell specificities. We hypothesize that T cell responses to specific epitopes of SARS-CoV-2 will be critical for its control in infected patients across diverse HLA haplotypes, and that a comprehensive mapping of epitopes recognized by those who clear the virus and their cognate TCRs will facilitate the development of the most effective vaccines for COVID-19 treatment. To pursue this hypothesis, we will employ some very new tools for T cell responses that have recently been developed at Stanford and the Princess Margaret Cancer Center, together with COVID-19 survivors’ blood samples obtained in Toronto, Hong Kong and Stanford.", "keywords": [ "2019-nCoV", "Affect", "Affinity", "Aliquot", "Alleles", "Antigenic Specificity", "Antigens", "Asia", "Attention", "Avidity", "Basic Science", "Biological Assay", "Biotinylation", "Blood", "Blood Banks", "Blood Cells", "Blood specimen", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19", "COVID-19 vaccine", "Cancer Center", "Cell Line", "Cells", "Chemicals", "China", "Clinical Sciences", "Cloning", "Cohort Studies", "Common Epitope", "Complex", "Computer software", "Containment", "Country", "Cytometry", "Data", "Development", "Dextrans", "Disease", "Elements", "Enzymes", "Epidemic", "Epitope Mapping", "Epitopes", "European", "Ferritin", "Flow Cytometry", "Fluorescence-Activated Cell Sorting", "Freezing", "Frequencies", "Genetic Transcription", "Genotype", "Haplotypes", "Hong Kong", "Immunologic Monitoring", "Immunologics", "Immunology", "In Vitro", "Individual", "Infection", "Influenza", "Influenza vaccination", "Institutional Review Boards", "Interferon Type II", "Interleukin-2", "Interleukin-6", "Label", "Length", "Link", "Longitudinal cohort", "M. tuberculosis genome", "Maps", "Mediating", "Medical", "Memory", "Methods", "Middle East Respiratory Syndrome Coronavirus", "Noise", "Open Reading Frames", "Organoids", "Patients", "Peptide/MHC Complex", "Peptides", "Peripheral Blood Mononuclear Cell", "Persons", "Phase", "Phenotype", "Physiologic pulse", "Polymers", "Population", "Production", "Proteins", "Publishing", "RNA Viruses", "Reagent", "Regulatory T-Lymphocyte", "Reporter", "Research", "SARS coronavirus", "Sampling", "Serum", "Signal Transduction", "Site", "Source", "Specificity", "Stains", "Streptavidin", "Structure", "Survivors", "System", "T cell response", "T memory cell", "T-Cell Immunologic Specificity", "T-Cell Receptor", "T-Cell Receptor Genes", "T-Lymphocyte", "T-Lymphocyte Epitopes", "T-cell receptor repertoire", "Technology", "Therapeutic", "Time", "Tonsil", "Travel", "Vaccination", "Vaccines", "Viral", "Virus", "Work", "World Health Organization", "antiviral immunity", "base", "cell type", "cohort", "cytokine", "cytotoxicity", "experience", "fluorophore", "genomic platform", "high throughput screening", "improved", "magnetic beads", "member", "molecular sequence database", "mortality", "nanoparticle", "novel", "pandemic disease", "patient screening", "peripheral blood", "protein aminoacid sequence", "response", "single cell analysis", "single cell sequencing", "single-" ], "approved": true } }, { "type": "Grant", "id": "6769", "attributes": { "award_id": "3UM1AI068614-17S5", "title": "CoVPN 3001 GY16 PostMerger LOC", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6245, "first_name": "Philip O.", "last_name": "Renzullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2006-06-29", "end_date": "2027-11-30", "award_amount": 3879990, "principal_investigator": { "id": 6246, "first_name": "Dan H.", "last_name": "Barouch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 6247, "first_name": "Lawrence", "last_name": "Corey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 6248, "first_name": "Glenda E", "last_name": "Gray", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 6249, "first_name": "GEORGIA Doris", "last_name": "TOMARAS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 758, "ror": "https://ror.org/007ps6h72", "name": "Fred Hutchinson Cancer Center", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for continuing implementation of the first COVID-19 vaccine efficacy trial “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 (Moderna) Vaccine in Adults Aged 18 Years and Older.” With the global COVID-19 pandemic, we recognize a significant need for vaccines that modify COVID-19 in SARS-CoV-2 infected individuals. Addressing this gap, the HVTN has joined 4 other National Institute of Health (NIH) clinical trial networks to form the CoVPN, an enhanced network dedicated to developing globally effective vaccines for SARS-CoV-2. Due to its extensive experience implementing HIV vaccine trials, the HIV Vaccine Trials Network (HVTN) LOC was selected to as the CoVPN vaccine LOC. This trial, a phase 3, placebo-controlled, double-blinded study will test the efficacy of mRNA-1273 SARS-CoV- 2, a lipid co-formulated messenger ribonucleic acid (mRNA) vaccine encoding the SARS-CoV-2 spike protein (S), to modify COVID-19 disease in adults 18 year of age and older. Participants will be recruited from clinical trial sites across the US, using data analytics to target high risk individuals with a diverse racial and ethnic profile. In addition, the CoVPN will use accessory community-based sites, staffed by clinical teams from the home sites and employ mobile clinics to enroll individuals in new high risk settings (e.g., meat packing plants). Participants will receive symptomatic screening for SARS-CoV-2 infection, and if they become infected will be monitored with frequent clinical check-ins and remote monitoring of vital signs. Infected individuals who progress to moderate-severe COVID-19 will be referred for hospitalization. All trial endpoint assays will be done at CoVPN laboratories, using validated assays for diagnosis and immune monitoring. Specific aims of this study are to demonstrate efficacy of mRNA-1273 SARS-CoV-2 to prevent COVID-19, to evaluate the safety and reactogenicity of 2 injections given 28 days apart, the assess the ability to prevent infection with SARS-CoV-2, the assess the ability to modify COVID-19 infection, to evaluate viral infection kinetics, and to evaluate the vaccine induced immune response. A booster injection (3rd dose) will be offered to participants at least 6 months after the last dose of the primary series. This efficacy trial will tell us much about the adaptive immune response in persons who receive three doses of an mRNA SARS-CoV-2 S protein-based vaccine and about their ability to modify the disease course of COVID-19 against current circulating strains. In addition, It will improve our understanding of the dynamics and duration of these responses. Lastly, the results of this trial will enable assessment for rare side effects, such as cardiomyopathy, that wouldn’t otherwise be detected in smaller clinical trials. 1", "keywords": [ "18 year old", "2019-nCoV", "Address", "Adult", "Age-Years", "Award", "Biological Assay", "Biometry", "COVID-19", "COVID-19 Prevention Network", "COVID-19 outbreak", "COVID-19 pandemic", "COVID-19 prevention", "COVID-19 screening", "COVID-19 severity", "COVID-19 vaccine", "Cardiomyopathies", "Clinic", "Clinical", "Clinical Trials", "Clinical Trials Network", "Code", "Communities", "Data Analytics", "Diagnosis", "Disease", "Dose", "Double-Blind Method", "Emergency Situation", "End Point Assay", "Enrollment", "Goals", "HIV Vaccine Trials Network", "HIV vaccine", "Health", "Home", "Hospitalization", "Immune response", "Immunity", "Immunologic Monitoring", "Individual", "Infection prevention", "Injections", "Kinetics", "Laboratories", "Lead", "Leadership", "Lipids", "Meat", "Monitor", "Parents", "Participant", "Persons", "Phase", "Placebo Control", "Plants", "Population", "Protocols documentation", "RNA", "Randomized", "Risk", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "Safety", "Series", "Site", "United States National Institutes of Health", "Vaccines", "Virus Diseases", "adaptive immune response", "base", "blind", "efficacy evaluation", "efficacy testing", "efficacy trial", "experience", "high risk", "immunogenicity", "improved", "operation", "placebo controlled study", "racial and ethnic", "racial diversity", "recruit", "remote monitoring", "response", "severe COVID-19", "side effect", "vaccine evaluation", "vaccine trial" ], "approved": true } }, { "type": "Grant", "id": "10621", "attributes": { "award_id": "75N91019D00024-0-759102200021-1", "title": "NIAID / CHILDRENS NATIONAL MEDICAL CENTER JOINT CLINICAL RESEARCH PROGRAM (JCRP) IMMUNOLOGIC AND INFECTIOUS DISEASES CLINICAL RESEARCH", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-02", "end_date": "2026-09-01", "award_amount": 3893764, "principal_investigator": { "id": 26665, "first_name": "KEVIN", "last_name": "NEWELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population (aged 0-21 years), including coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C).", "keywords": [ "2019-nCoV", "COVID-19", "Child", "Childhood", "Clinical", "Clinical Research", "Communicable Diseases", "Evaluation", "Genetic", "Household", "Immune System Diseases", "Immune response", "Incidence", "Joints", "Medical", "Medical center", "Multisystem Inflammatory Syndrome in Children", "National Institute of Allergy and Infectious Disease", "Observational Study", "Outcome", "Population", "Prevalence", "Recovery", "Role", "SARS-CoV-2 infection", "Survivors", "aged", "biobank", "pediatric patients", "programs", "prospective" ], "approved": true } }, { "type": "Grant", "id": "10514", "attributes": { "award_id": "1G20AI174728-01", "title": "A Bedside-to-Bench Approach to Pandemic Preparedness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-02-29", "award_amount": 3906967, "principal_investigator": { "id": 26522, "first_name": "KENNETH W.", "last_name": "BAYLES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 628, "ror": "https://ror.org/00thqtb16", "name": "University of Nebraska Medical Center", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true }, "abstract": "The clinical capabilities of the University of Nebraska Medical Center (UNMC) and its clinical partner, Nebraska Medicine (NM), played vital roles in the treatment of U.S. citizens infected with Ebola in 2014 and the early response to the COVID-19 pandemic. While the presence of the National Quarantine Unit (NQU) and the Nebraska Biocontainment Unit (NBU) on campus provided UNMC researchers with some of the earliest access to individuals exposed to infectious agents (in the NQU), as well as those who begin to develop disease (in the NBU), we recognized a key gap in our capabilities is the lack of modern technologies within our high- containment spaces required to gain greater insights into the pathogenic mechanisms utilized by new and emerging pathogens. Therefore, the overall goal of this proposed project is to modernize our high-containment research laboratories to maximize their research potential and to leverage our clinical expertise to foster research on vaccine and therapeutic development. This will be achieved in two ways: First, we will improve our biocontainment infrastructure within key biocontainment research facilities in a way that increases our capacity to conduct research on high-consequence pathogens, maximizes synergy between the various biocontainment laboratories, and increases biosecurity. Second, we will invest in the modern technologies needed in our BSL-3 and ABSL-3 laboratories to conduct cutting-edge studies on new and emerging pathogens and to address critical questions related to disease pathogenesis. Upon completion, these improvements will foster much greater synergy between the clinical and research arms of UNMC and NM, leveraging early access to clinical data/samples to streamline research into disease pathogenesis, and to accelerate the development of new vaccines and therapeutics during future pandemics.", "keywords": [ "Address", "Animal Model", "COVID-19 pandemic", "Cell Separation", "Cell physiology", "Clinical", "Clinical Data", "Clinical Research", "Communicable Diseases", "Containment", "Decontamination", "Development", "Diagnostic", "Disease", "Ebola", "Enhancement Technology", "Environment", "Equipment", "Event", "Exposure to", "Faculty", "Fostering", "Future", "Goals", "Human Resources", "Individual", "Infection", "Infectious Agent", "Infectious Diseases Research", "Infrastructure", "Investments", "Laboratories", "Laboratory Research", "Medical center", "Medicine", "Microscopy", "Modernization", "Nebraska", "Pathogenesis", "Pathogenicity", "Patients", "Play", "Quarantine", "Research", "Research Personnel", "Role", "Sampling", "Standardization", "Technology", "Universities", "Update", "Work", "arm", "bench to bedside", "biocontainment facility", "biosecurity", "diagnostic assay", "emerging pathogen", "high efficiency particulate air filter", "improved", "insight", "interoperability", "laboratory development", "novel diagnostics", "novel therapeutics", "novel vaccines", "pandemic disease", "pandemic preparedness", "pathogen", "recruit", "research facility", "response", "synergism", "therapeutic development", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "4354", "attributes": { "award_id": "1440149", "title": "USGCRP Support for International START Secretariat", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Geosciences (GEO)", "Integrat & Collab Ed & Rsearch" ], "program_reference_codes": [], "program_officials": [ { "id": 14817, "first_name": "Maria", "last_name": "Uhle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-02-01", "end_date": "2021-01-31", "award_amount": 3923577, "principal_investigator": { "id": 14819, "first_name": "Jon", "last_name": "Padgham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1270, "ror": "", "name": "START International, Inc.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 14818, "first_name": "Sarah E", "last_name": "Schweizer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1270, "ror": "", "name": "START International, Inc.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "This award provides support from the US Global Change Research Program for the Secretariat operations of the global change SysTem for Analysis, Research, and Training (START). This organization is an essential component of the US Global Change Research Program strategic plan as it relates to international engagement. START?s mission \"to increase opportunities for research, education and training that strengthen scientific capacities in developing countries to understand, communicate and motivate action on critical global change challenges\" addresses all of the US Global Change Research Program strategic goals. The funding will enable START Secretariat to continue developing and implementing programs that advance ?research-driven capacity building? in Africa and Asia. This approach emphasizes experiential learning by doing, particularly for early-career scientists, in which targeted skill building and networking opportunities are integrated into research on regional impacts and risks stemming from global change. START?s work focuses on critical challenges at the intersection of global/climate change and sustainable development, including disaster risk reduction, land-use/land-cover change, biodiversity conservation, urban development, human health, water resources management, and agriculture and food security.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8330", "attributes": { "award_id": "75N95021D00001-0-759502100002-1", "title": "TASK ORDER NO. 2, STSS PROGRAM SUPPORT AND TRANSITION-IN (2)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-05-01", "end_date": "2021-06-30", "award_amount": 3927445, "principal_investigator": { "id": 24128, "first_name": "SUHAS", "last_name": "SHARMA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The NCATS National COVID Cohort Collaborative (N3C) Data Enclave, a centralized and secure data platform featuring powerful analytics capabilities for online discovery, visualization and collaboration for researchers studying COVID-19. The data are robust in scale and scope and are transformed into a harmonized data set to help scientists study COVID 19, including potential risk factors, protective factors and long-term health consequences. The N3C Data Enclave is anticipated to be one of the largest collections of data on COVID-19 patients in the United States. Data analysis within the enclave is supported by both R and Python, the most widely used open-source platforms for statistical analysis and data science. Researchers requesting access to, or working within, the enclave are encouraged to assemble collaborative teams with diverse expertise in such areas as clinical research, statistical analysis and informatics to make the best use of the N3C Data Enclave. A core tenet of the enclave is that it is both accessible and secure, allowing researchers to pursue research in a safe environment conducive to collaborative discovery while also allowing for the deployment of a wide variety of open source tools and components.", "keywords": [ "Area", "COVID-19", "COVID-19 patient", "Clinical Research", "Collaborations", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Environment", "Health", "Informatics", "Pythons", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Statistical Data Interpretation", "United States", "Visualization", "cohort", "coronavirus disease", "data enclave", "data harmonization", "open source", "open source tool", "programs", "protective factors" ], "approved": true } }, { "type": "Grant", "id": "11190", "attributes": { "award_id": "1U01AI174268-01", "title": "TB-RICC 3.0", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27204, "first_name": "SUDHA", "last_name": "SRINIVASAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-04-01", "end_date": "2028-03-31", "award_amount": 3933417, "principal_investigator": { "id": 27205, "first_name": "BRUNO DE BEZERRIL", "last_name": "ANDRADE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27206, "first_name": "Jerrold J.", "last_name": "Ellner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27207, "first_name": "TIMOTHY R", "last_name": "STERLING", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1856, "ror": "", "name": "RUTGERS BIOMEDICAL AND HEALTH SCIENCES", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "TB-RICC 3.0 is designed to support the Regional Prospective Observational Research Tuberculosis (RePORT) Consortium to produce the highest quality observational and interventional research on tuberculosis (TB), TB-HIV, and TB-COVID-19. To accomplish this goal, TB-RICC 3.0 will: i) collaborate with RePORT Country-Network Data Centers and Biorepositories to ensure that common data elements (CDE) of the Common Protocol and Specimen Tracking are accessible through the Global Data Template; ii) organize and/or strengthen select sites to participate in diagnostic studies and clinical trials; and iii) support the RePORT Country-Networks to ensure further development of TB diagnostic laboratories, TB- RICC 3.0 specialized laboratories, and biorepositories. Aims of TB-RICC 3.0 are: Coordinating Center Structure and Function: develop a Leadership Group and Executive Committee; assure effective communication internally and externally; establish a Data Hub to provide seamless data management from collection to analysis; establish Scientific Working Groups; a Scientific Review Committee and an Administrative Core; facilitate grant submissions to potential funders and partners. Data Harmonization: Develop a data hub to collaborate with country-level data centers to facilitate multiregional data workflow using the REDCap Harmonist platform and other tools; Research: catalyze TB, TB/HIV and TB/COVID-19 research within and across RePORT Country Networks, and with external partners; prioritize study of TB close contacts to evaluate biomarkers predictive of progression to TB across three “omics” platforms and three continents; Capacity Building: develop modular remote courses for capacity building in the components of TB research; Mentor early-stage investigator (ESI) development. TB-RICC 3.0 will deliver high-impact innovative research to advance TB Science and TB Control", "keywords": [ "Africa", "Architecture", "Area", "Asia", "Biological Markers", "Biometry", "Biotechnology", "Brazil", "COVID-19", "China", "Clinical", "Clinical Research", "Clinical Trials", "Cohort Studies", "Collaborations", "Collection", "Common Data Element", "Communication", "Country", "Data", "Data Collection", "Data Element", "Development", "Diagnostic", "Diagnostics Research", "Elements", "Ensure", "Epidemiology", "Feedback", "Foundations", "Generations", "Geographic Locations", "Goals", "Grant", "HIV/TB", "Human", "Immunology", "India", "Indonesia", "International", "Intervention Studies", "Korea", "Laboratories", "Leadership", "Logistics", "Mentors", "Monitor", "Observational Study", "Performance", "Pharmaceutical Preparations", "Population", "Proteomics", "Protocols documentation", "Publishing", "Quality Control", "Research", "Research Design", "Research Methodology", "Research Personnel", "Research Support", "Review Committee", "Science", "Site", "South Africa", "South America", "Specimen", "Structure", "Technology", "Translational Research", "Treatment outcome", "Tuberculosis", "Vaccines", "Validation", "biobank", "biomarker evaluation", "data centers", "data harmonization", "data hub", "data management", "data standards", "design", "electronic data", "falls", "frontier", "innovation", "insight", "learning materials", "multiple omics", "nano-string", "novel diagnostics", "predictive marker", "programs", "prospective", "response", "sample collection", "tool", "transcriptomics", "tuberculosis diagnostics", "working group" ], "approved": true } }, { "type": "Grant", "id": "10563", "attributes": { "award_id": "1U54MD015959-01A1", "title": "Interdisciplinary Health Equity Research (IHER) Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 23654, "first_name": "YEWANDE A", "last_name": "Oladeinde", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 3945011, "principal_investigator": { "id": 26580, "first_name": "Sangeeta", "last_name": "Gupta", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 24978, "first_name": "MELISSA A", "last_name": "HARRINGTON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1165, "ror": "https://ror.org/03g35dg18", "name": "Delaware State University", "address": "", "city": "", "state": "DE", "zip": "", "country": "United States", "approved": true }, "abstract": "Interdisciplinary Health Equity Research (IHER) Center Summary The COVID-19 pandemic put a spotlight on our nation’s stark disparities in health and the disproportional burden of disease related to race, ethnicity, and socioeconomic status. Delaware is an ideal state for a health disparities-focused research center as it represents the whole of the USA in a compact form. The population of Delaware (~978,000) mirrors the US population in ratios of urban-to-rural, old to young, and ethnic/racial diversity. Thus, studies involving a cross-section of Delaware are easily generalizable to the national population. In addition, Delaware is ranked 35th out of the 50 states for overall health outcomes, a low ranking that reflects high disparities in health status for low-income and minority populations. The urgency to address health disparities in Delaware is clear, and promoting health equity through a social determinants of health approach is a state priority. Delaware State University is well-positioned to lead that effort. DSU’s Interdisciplinary Health Equity Research Center has the overall goal to develop DSU as a leader in biomedical, behavioral and social research related to health conditions that have a disparate impact on underserved individuals and communities. The Center will build a supportive scientific community that brings together faculty investigating the social and behavioral determinants of health with faculty using biomedical approaches to investigate health conditions that have a disparate impact on underserved populations. The IHER Center will build a research-enabling infrastructure at DSU by: a) providing access to core facilities in biostatistics, qualitative methods, microscopy and electrophysiology; b) providing investigators working with human subjects support for managing the IRB process, and an infrastructure for secure collection, analysis and storage of human subject data; and c) immersing researchers in a supportive professional network. We will also build our IHER Center by recruiting two new faculty members with expertise in behavioral and social research related to health equity, and supporting them to work with other DSU scientists in interdisciplinary research teams. Through mentorship, career enhancement activities, and a Pilot Grant Program for early-stage investigators, our IHER Center will develop faculty at DSU into independent investigators who can successfully lead interdisciplinary research teams and compete for external funding DSU is currently engaged in robust initiatives to promote health equity, including DSU’s Center for Neighborhood Revitalization and Research, Health Disparities Center; and an NIH RADx-UP grant. Our IHER Center will leverage Delaware State University’s expanding human and research resources in biomedical research, our state-wide partnerships with other Delaware institutions and community based organizations, as well as the nationwide RCMI Translational Research Network to promote health equity, social awareness and economic development among local communities.", "keywords": [ "Address", "African American", "Alzheimer&apos", "s disease diagnostic", "Applications Grants", "Asian", "Awareness", "Beds", "Behavioral", "Behavioral Research", "Biological", "Biomedical Research", "Biometry", "COVID-19", "COVID-19 pandemic", "Caucasians", "Clinical", "Collection", "Communities", "Core Facility", "Data", "Delaware", "Development", "Dissemination and Implementation", "Economic Development", "Electrophysiology (science)", "Ethnic Origin", "Event", "Faculty", "Fostering", "Funding", "Future", "Goals", "Grant", "Health", "Health Sciences", "Health Status", "Hispanic", "Historically Black Colleges and Universities", "Human Resources", "Individual", "Infrastructure", "Institution", "Institutional Review Boards", "Interdisciplinary Study", "Intervention", "Lead", "Link", "Low income", "Mentors", "Mentorship", "Microscopy", "Minority Groups", "Native Americans", "Neighborhoods", "Nursing Research", "Outcome", "Outcomes Research", "Patient Education", "Patient-Focused Outcomes", "Pilot Projects", "Population", "Positioning Attribute", "Process", "Qualitative Methods", "Qualitative Research", "RADx Underserved Populations", "Race", "Recording of previous events", "Reduce health disparities", "Reporting", "Research", "Research Personnel", "Research Project Grants", "Resources", "Rural", "SARS-CoV-2 infection", "Science", "Scientist", "Scourge", "Secure", "Socioeconomic Status", "Structure", "Students", "Targeted Research", "Testing", "Training", "Translating", "Translational Research", "Trust", "Underrepresented Minority", "Underrepresented Populations", "Underserved Population", "United States", "United States National Institutes of Health", "Universities", "Work", "base", "burden of illness", "career", "career development", "career networking", "clinical care", "collaborative approach", "community engagement", "contextual factors", "ethnic health disparity", "experience", "faculty support", "falls", "health care disparity", "health disparity", "health equity", "health equity promotion", "human subject", "improved", "innovation", "interdisciplinary collaboration", "literacy", "meetings", "member", "mid-career faculty", "minority communities", "molecular diagnostics", "next generation", "programs", "public health relevance", "racial and ethnic", "racial diversity", "recruit", "research and development", "social", "social health determinants" ], "approved": true } }, { "type": "Grant", "id": "6605", "attributes": { "award_id": "3U54EB015408-09S2", "title": "Point of Care Technology Research Center in Primary Care", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22147, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2012-07-01", "end_date": "2023-05-31", "award_amount": 3947568, "principal_investigator": { "id": 22148, "first_name": "John A", "last_name": "Parrish", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 22149, "first_name": "Steven", "last_name": "Schachter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Overall The Point-of-Care Technology Research Center in Primary Care proposes to further develop a national “center-without-walls” for rapid transformation of emerging point-of-care technologies into commercially viable, clinically focused solutions for improving primary healthcare. The Center was established by the Consortia for Improving Medicine through Innovation and Technology (CIMIT), a consortium of research institutions, universities, military medicine centers and hospitals throughout the US with international affiliates at University of Manchester-UK (MIMIT), Barcelona (The Center for the Integration of Medicine and Innovative Technologies in Catalonia) and Singapore (A*-STAR/Eastern Health Alliance). CIMIT established the Point-of- Care Technology Research Center in Primary Care under a Cooperative Agreement (U54) award from National Institute of Biomedical Imaging and Bioengineering (NIBIB) in 2012 and the Center created a national network of research sites, harnessing the power of multidisciplinary collaboration to speed the translation of high-impact research into primary care practice and broader dissemination by commercially licensable opportunities. We will build upon our proven approach to needs-driven primary healthcare technology innovation to expand and significantly enhance our Center. The Center’s overall objective is to build upon the progress made under the previous U54 award and offer expanded support to teams through the integrated functional elements of the proposed enhanced Center. In so doing, the Center will offer a portfolio of synergistic support to teams with innovative solutions through defined interfaces and hand offs throughout the innovation process while continuously improving the Center’s processes of finding, funding, facilitating, and following projects. The long-term goal is to create a dynamic, sustainable national network that identifies key unmet needs in the delivery of primary care as well as promising emerging technologies and then to accelerate their translation into clinical applications for broad impact in primary care medicine through high-quality translational and clinical research.", "keywords": [ "Address", "Area", "Award", "Caring", "Chronic Disease", "Clinical", "Clinical Research", "Collaborations", "Elements", "Emerging Technologies", "Engineering", "Environment", "Funding", "Goals", "Hand", "Health", "Health Alliance", "Health Technology", "Healthcare", "Hospitals", "Institution", "Interdisciplinary Study", "International", "Laboratories", "Licensing", "Medicine", "Methodology", "Military Medicine", "Modeling", "National Institute of Biomedical Imaging and Bioengineering", "Outcome", "Patients", "Performance", "Point of Care Technology", "Primary Care Physician", "Primary Health Care", "Process", "Recommendation", "Research", "Resources", "Scientist", "Singapore", "Site", "Speed", "Students", "Technology", "Testing", "Training", "Translational Research", "Translations", "U-Series Cooperative Agreements", "Universities", "aging population", "care providers", "clinical application", "commercialization", "design", "experience", "follow-up", "improved", "industry partner", "innovation", "innovative technologies", "meetings", "point of care", "prototype" ], "approved": true } }, { "type": "Grant", "id": "15360", "attributes": { "award_id": "1UG3DA059278-01A1", "title": "Development of SBS-226, a MOR agonist / DOR antagonist, for OUD", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 31959, "first_name": "David A", "last_name": "White", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-30", "end_date": "2026-08-31", "award_amount": 3957359, "principal_investigator": { "id": 31960, "first_name": "Jeffrey", "last_name": "Reich", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2537, "ror": "", "name": "SPARIAN BIOSCIENCES, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Opioid use disorder (OUD) is a chronic disorder characterized by the repeated, compulsive use of opioid drugs with a detrimental impact to one’s physical, social, and psychological wellbeing. The use of prescription opiates is often necessary to control moderate to severe levels of pain. However, about 10% of patients prescribed an opiate for a medical condition are at risk for developing OUD. Opiate Use Disorder is a global problem but is at crisis levels in the U.S with significant mortality. It is estimated in this country that about ~11M misuse opioids, ~5.6M people have OUD and close to 80K died from opioid related overdoses. Sadly, the COVID epidemic has worsened the epidemic by increasing risk factors for OUD and occurred at a time when fentanyl has flooded the supply. Current treatments are primarily buprenorphine and methadone. Despite treatment options, OUD is difficult to effectively treat long-term due to access, stigma, and efficacy of the compounds. Mitragyna speciosa, a plant commonly known as kratom, has anecdotally been used for treatment of opiate withdrawal and OUD. The naturally occurring active substance is believed to be mitragynine and the 7- OH mitragynine (7OH) metabolite which act through the mu opioid receptor. An active metabolite of mitragynine, 7OH mitragynine, demonstrates MOR agonist properties such as analgesia, tolerance, physical dependence, and reinforcing effects. In contrast, an analog of mitragynine named 9-methoxy corynantheidine pseudoindoxyl (9CP) has a very different receptor binding profile and in vivo properties. 9CP is an partial agonist at MOR and it is also a delta opioid receptor (DOR) antagonist. Unlike the natural products found in kratom, when studied in mice under acute dosing 9CP is non-addictive, and demonstrates far less respiratory depression, tolerance, and signs of physical dependence than morphine. Most importantly, in mice, 9CP can ameliorate naloxone-precipitated withdrawal in morphine-dependent mice. Sparian has created a series of 9CP analogs and screened them across CMC, ADME, and PK properties and identified a lead candidate – SBS-226. Therefore, as an innovative pharmacological approach, we propose the development of SBS-226 as a novel selective, potent and non-addictive chemical entity utilizing mixed MOR agonism/DOR antagonism for the treatment of OUD. In the present application, we propose a full IND-enabling development plan and Phase 1 clinical trial.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1419, "count": 14184 } } }